Selumetinib for Paediatric Patients: What This Means for Future Treatment?

Selumetinib for Paediatric Patients: What This Means for Future Treatment?

User Photo
Cancer-News

1 month
2 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Brigitte C. Widemann, MD and Andrea Gross, MD of National Cancer Institute discuss selumetinib, the first medicine approved to treat paediatric patients with neurofibromatosis type 1 plexiform neurofibromas, a rare and debilitating genetic condition. More here: https://www.astrazeneca.com/media-centre/press-releases/2020/koselugo-selumetinib-approved-in-us-for-paediatric-patients-with-neurofibromatosis-type-1-plexiform-neurofibromas.html
Up Next Autoplay
User Photo